Portal de Periódicos da CAPES

Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft

2013; Lippincott Williams & Wilkins; Volume: 27; Issue: 16 Linguagem: Inglês

10.1097/01.aids.0000432539.77711.f4

1473-5571

Térésa Antonini, Valérie Furlan, Elina Teicher, Stéphanie Haïm‐Boukobza, Mylène Sebagh, Audrey Coilly, Laurence Bonhomme‐Faivre, Gilles Peytavin, Anne‐Marie Roque‐Afonso, Daniel Vittecoq, Didier Samuel, Anne‐Marie Taburet, Jean‐Charles Duclos‐Vallée,

HIV/AIDS drug development and treatment

We report, for the first time, the outcome of anti-hepatitis C virus (HCV) triple therapy with telaprevir in an HIV/HCV co-infected transplanted patient. After liver transplantation, the patient experienced a severe HCV recurrence with fibrosing cholestatic hepatitis, and anti-HCV therapy with pegylated interferon alpha 2a, ribavirin and telaprevir was initiated. A sustained virological response was achieved after 48 weeks of anti-HCV therapy. Drug-drug interactions between antiretroviral therapy, immunosuppressive agents and anti-HCV therapy could be managed.